GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARsgen Therapeutics Holdings Ltd (HKSE:02171) » Definitions » Debt-to-Revenue

CARsgen Therapeutics Holdings (HKSE:02171) Debt-to-Revenue : 2.52 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is CARsgen Therapeutics Holdings Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

CARsgen Therapeutics Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was HK$36.01 Mil. CARsgen Therapeutics Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was HK$141.67 Mil. CARsgen Therapeutics Holdings's annualized Revenue for the quarter that ended in Dec. 2024 was HK$70.65 Mil. CARsgen Therapeutics Holdings's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 2.52.

CARsgen Therapeutics Holdings Debt-to-Revenue Historical Data

The historical data trend for CARsgen Therapeutics Holdings's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CARsgen Therapeutics Holdings Debt-to-Revenue Chart

CARsgen Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial N/A 13.10 N/A N/A 4.22

CARsgen Therapeutics Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A 16.81 2.52

Competitive Comparison of CARsgen Therapeutics Holdings's Debt-to-Revenue

For the Biotechnology subindustry, CARsgen Therapeutics Holdings's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CARsgen Therapeutics Holdings's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARsgen Therapeutics Holdings's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where CARsgen Therapeutics Holdings's Debt-to-Revenue falls into.


;
;

CARsgen Therapeutics Holdings Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

CARsgen Therapeutics Holdings's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(36.01 + 141.674) / 42.093
=4.22

CARsgen Therapeutics Holdings's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(36.01 + 141.674) / 70.648
=2.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2024) Revenue data.

CARsgen Therapeutics Holdings Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of CARsgen Therapeutics Holdings's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

CARsgen Therapeutics Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARsgen Therapeutics Holdings Ltd (HKSE:02171) » Definitions » Debt-to-Revenue
Comparable Companies
HKSE:09966 HKSE:01672 HKSE:02157 HKSE:02142 HKSE:02315 HKSE:02105 HKSE:02256 HKSE:00775 HKSE:02480 HKSE:06660 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
No. 466 Yindu Road, Building 2, 1st Floor, Xuhui District, Shanghai, CHN
Website
https://www.carsgen.com
CARsgen Therapeutics Holdings Ltd is a clinical-stage biopharmaceutical company discovering, researching, and developing cell therapies in the People's Republic of China and the United States of America.
Executives
Bei Jing Shen Nong Tou Zi Guan Li Gu Fen You Xian Gong Si 2102 Investment manager
Candock Holdings Limited 2501 Other
Yi Jie Sheng Wu Ji Shu Kong Gu You Xian Gong Si 2501 Other
Yi De Kong Gu You Xian Gong Si 2501 Other
Quan Zhou Shi Ding Wo Chuang Feng Tou Zi Zhong Xin You Xian He Huo 2501 Other
Yang Xuehong 2501 Other
Wang Huamao 2401 A concert party to an agreement to buy shares
Li Zonghai 2401 A concert party to an agreement to buy shares
Guo Bingsen 2401 A concert party to an agreement to buy shares
Accure Biotech Limited 2501 Other
Cart Biotech Limited 2501 Other
Chen Haiou 2501 Other
Guo Xiaojing 2501 Other
He Xi Holdings Limited 2501 Other
Redelle Holding Limited 2501 Other

CARsgen Therapeutics Holdings Headlines

No Headlines